1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Onychomycosis (Tinea Unguium) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

SUMMARY
DelveInsight’s, “ Onychomycosis (Tinea Unguium)- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:
- A snapshot of the global Market therapeutics scenario for Onychomycosis (Tinea Unguium).
- A review of the marketed products under prescription for Onychomycosis (Tinea Unguium), regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Onychomycosis (Tinea Unguium) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Onychomycosis (Tinea Unguium) drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Onychomycosis (Tinea Unguium) drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Onychomycosis (Tinea Unguium) drugs.
- Coverage of Onychomycosis (Tinea Unguium) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Onychomycosis (Tinea Unguium) key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Onychomycosis (Tinea Unguium).
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Onychomycosis (Tinea Unguium).
- API intelligence over marketed drugs for Onychomycosis (Tinea Unguium) and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Onychomycosis (Tinea Unguium).
- Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Onychomycosis (Tinea Unguium) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
Table of Contents
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Route of Synthesis
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Phase III Drugs Information
- Phase III Drugs Description
- The United States Drug Master Filings (US DMF)
- Discontinued Drugs Information


List of Tables

Onychomycosis (Tinea Unguium) Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Onychomycosis (Tinea Unguium) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Onychomycosis (Tinea Unguium) Therapeutic Market, US, (Year), 2014
Onychomycosis (Tinea Unguium) Marketed Drugs, API Manufacturers by US DMF Status, 2014
Onychomycosis (Tinea Unguium) Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Onychomycosis (Tinea Unguium) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Onychomycosis (Tinea Unguium) Therapeutic Market, Global Sales (in million USD), 2014
Onychomycosis (Tinea Unguium) Marketed Drugs, API Manufacturers, Global, 2014
Onychomycosis (Tinea Unguium) Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Onychomycosis (Tinea Unguium), 2014?


List of Figures

Onychomycosis (Tinea Unguium) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Onychomycosis (Tinea Unguium) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Onychomycosis (Tinea Unguium) Therapeutic Market, US, (Year), 2014
Onychomycosis (Tinea Unguium) Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Onychomycosis (Tinea Unguium) Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Onychomycosis (Tinea Unguium) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Onychomycosis (Tinea Unguium) Therapeutic Market, Global Sales (in million USD), 2014
Onychomycosis (Tinea Unguium) Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


Download Unlimited Documents from Trusted Public Sources

Infectious Disease Statistics in the US

  • December 2016
    32 pages
  • Infectious Dise...  

    Asthma  

  • United States  

View report >

Infectious Disease Statistics in Africa

  • December 2016
    3 pages
  • Infectious Dise...  

    Therapy  

    Pharmaceutical  

  • Africa  

    World  

View report >

Infectious Disease Statistics in Brazil

  • December 2016
    9 pages
  • Infectious Dise...  

    Hospital  

  • Brazil  

View report >

Related Market Segments :

Infectious Disease
Dermatological Condition

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.